Ultragenyx Pharmaceutical Inc (RARE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.30+3.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RARE
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-0.6) + peer(0.2*0.0) + term(0.0) → -0.21% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 4, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2026 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Results of Operations and Financial Condition. On May 5, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Results of Operations and Financial Condition. On February 12, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing its financial results for the three months ended December 31, 2025 and for the year ended December 31, 2025 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under
Results of Operations and Financial Condition. On January 12, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary unaudited fiscal year 2025 total revenue results, revenue for Crysvita® and revenue for Dojolvi®and cash and investments at 2025 fiscal year end. The Company expects to report its full year results for the 2025 fiscal year in February 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1. The in…
Results of Operations and Financial Condition. On November 4, 2025, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended September 30, 2025 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Results of Operations and Financial Condition. On August 5, 2025, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended June 30, 2025 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Results of Operations and Financial Condition. On May 6, 2025, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended March 31, 2025 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under
Results of Operations and Financial Condition. On February 13, 2025, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2024 and for the year ended December 31, 2024 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under
Results of Operations and Financial Condition. On January 12, 2025, Ultragenyx Pharmaceutical Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing preliminary unaudited fiscal year 2024 total revenue results, revenue for Crysvita® and revenue for Dojolvi®, cash, cash equivalents and available-for-sale investments at 2024 fiscal year end and financial guidance for 2025. The Company expects to report its full year results for the 2024 fiscal year in February 2025. A…
Results of Operations and Financial Condition. On November 5, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended September 30, 2024 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Results of Operations and Financial Condition. On August 1, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended June 30, 2024 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Results of Operations and Financial Condition. On May 2, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended March 31, 2024 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under
Results of Operations and Financial Condition. On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023 (the “ Press Release ”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.